Literature DB >> 2980437

Magnetic resonance imaging does not define tumor boundaries.

L D Lunsford1, A J Martinez, R E Latchaw.   

Abstract

To define tumor boundaries prior to radiation therapy, 13 patients with intracranial glial neoplasms had tumor biopsies using magnetic resonance imaging (MRI)--computed tomography (CT) stereotactic technique. Precise histologic sampling of the lesion volume was correlated with the MRI and CT-defined 'lesion'. Tumor boundaries extended beyond the CT or MRI margin in 4 of 4 cases of glioblastoma, 1 of 3 cases of anaplastic astrocytoma, and 1 of 6 cases of well-differentiated astrocytoma. While stereotactic MRI is superior to stereotactic CT in the visualization of glial neoplasms, accurate tumor biopsy is mandatory to define both tumor type and margins before pre-operative radiation therapy.

Entities:  

Mesh:

Year:  1986        PMID: 2980437

Source DB:  PubMed          Journal:  Acta Radiol Suppl        ISSN: 0365-5954


  21 in total

1.  Estimation of tumor volume with fuzzy-connectedness segmentation of MR images.

Authors:  Gul Moonis; Jianguo Liu; Jayaram K Udupa; David B Hackney
Journal:  AJNR Am J Neuroradiol       Date:  2002-03       Impact factor: 3.825

2.  Whole-brain N-acetylaspartate spectroscopy and diffusion tensor imaging in patients with newly diagnosed gliomas: a preliminary study.

Authors:  M Inglese; S Brown; G Johnson; M Law; E Knopp; O Gonen
Journal:  AJNR Am J Neuroradiol       Date:  2006 Nov-Dec       Impact factor: 3.825

3.  A combined diffusion tensor imaging and Ki-67 labeling index study for evaluating the extent of tumor infiltration using the F98 rat glioma model.

Authors:  Kai Wang; Tingting Ha; Xuzhu Chen; Shaowu Li; Lin Ai; Jun Ma; Jianping Dai
Journal:  J Neurooncol       Date:  2018-01-02       Impact factor: 4.130

4.  Assessing global invasion of newly diagnosed glial tumors with whole-brain proton MR spectroscopy.

Authors:  Benjamin A Cohen; Edmond A Knopp; Henry Rusinek; James S Babb; David Zagzag; Oded Gonen
Journal:  AJNR Am J Neuroradiol       Date:  2005-10       Impact factor: 3.825

5.  Outcome of radiosurgery for recurrent malignant gliomas: assessment of treatment response using relative cerebral blood volume.

Authors:  Hong Rye Kim; Se-Hwan Kim; Jung-Il Lee; Ho Jun Seol; Do-Hyun Nam; Sung Tae Kim; Kwan Park; Jong Hyun Kim; Doo-Sik Kong
Journal:  J Neurooncol       Date:  2014-12-09       Impact factor: 4.130

6.  Volumetry of [(11)C]-methionine PET uptake and MRI contrast enhancement in patients with recurrent glioblastoma multiforme.

Authors:  Norbert Galldiks; Roland Ullrich; Michael Schroeter; Gereon R Fink; Andreas H Jacobs; Lutz W Kracht
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-01       Impact factor: 9.236

7.  Quantitative characterization of the imaging limits of diffuse low-grade oligodendrogliomas.

Authors:  Chloé Gerin; Johan Pallud; Christophe Deroulers; Pascale Varlet; Catherine Oppenheim; Francois-Xavier Roux; Fabrice Chrétien; Stephen R Thomas; Basile Grammaticos; Mathilde Badoual
Journal:  Neuro Oncol       Date:  2013-06-14       Impact factor: 12.300

Review 8.  Whole-brain N-acetylaspartate as a surrogate marker of neuronal damage in diffuse neurologic disorders.

Authors:  D J Rigotti; M Inglese; O Gonen
Journal:  AJNR Am J Neuroradiol       Date:  2007-10-05       Impact factor: 3.825

9.  Survival following stereotactic radiosurgery for newly diagnosed and recurrent glioblastoma multiforme: a multicenter experience.

Authors:  Alan T Villavicencio; Sigita Burneikiene; Pantaleo Romanelli; Laura Fariselli; Lee McNeely; John D Lipani; Steven D Chang; E Lee Nelson; Melinda McIntyre; Giovanni Broggi; John R Adler
Journal:  Neurosurg Rev       Date:  2009-07-25       Impact factor: 3.042

10.  Discrepancy between lesion distributions on methionine PET and MR images in patients with glioblastoma multiforme: insight from a PET and MR fusion image study.

Authors:  K Miwa; J Shinoda; H Yano; A Okumura; T Iwama; T Nakashima; N Sakai
Journal:  J Neurol Neurosurg Psychiatry       Date:  2004-10       Impact factor: 10.154

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.